Pharma Focus Asia

AGC Biologics and BioConnection Join Forces to Offer Integrated Biopharmaceutical Development and Manufacturing Solutions

Thursday, May 23, 2024

AGC Biologics and BioConnection, a specialized contract manufacturing organization (CMO) with a focus on aseptic filling of vials and syringes, have formed a strategic partnership. This collaboration combines AGC Biologics' drug substance development and manufacturing capabilities with BioConnection's expertise in aseptic filling to provide end-to-end biopharmaceutical services.

The new partnership offers a streamlined, full-service solution for clinical-stage development and manufacturing, helping to expedite timelines and bring therapies to market more efficiently. By uniting their drug substance and drug product services, AGC Biologics and BioConnection now provide a "gene to vial" value chain service under a single contract with unified project management. This approach simplifies the process, eliminating the need for separate negotiations for drug substance and drug product contracts, and enables more efficient planning of drug filling activities.

In response to the proposed U.S. BIOSECURE Act, this partnership ensures a secure and reliable supply chain for biopharmaceutical development, manufacturing, and aseptic filling. With facilities in Japan, the United States, and Europe, the collaboration addresses global supply chain needs. AGC Biologics' extensive network and single-use bioreactor technology facilitate smooth transitions of platform processes, minimizing disruptions when changing outsourcing partners.

Together, AGC Biologics and BioConnection are well-equipped to meet the increasing demand for high-quality biopharmaceutical manufacturing services. AGC Biologics offers a wide range of services, from cell line development to commercial-scale manufacturing, across its global facilities. Their expertise includes microbial and mammalian-based systems, plasmid DNA (pDNA), and messenger RNA (mRNA). Known for its technical and scientific excellence, AGC Biologics has supported over a dozen commercial products since 2018.

BioConnection excels in aseptic filling of vials and syringes for both clinical and commercial production, including liquid and freeze-dried products. With state-of-the-art facilities and a skilled team, BioConnection ensures high standards of product quality and safety, earning a reputation for its customer-focused approach since 2005.

“Global pharmaceutical companies need reliable production and filling facilities for their drug products. By combining our resources with BioConnection, we offer a new end-to-end solution under one contract with AGC Biologics,” said Patricio Massera, CEO of AGC Biologics. “BioConnection’s capabilities enhance our biopharmaceutical services, allowing us to build stronger relationships with developers and help bring their products to patients.”

BioConnection, added, "We are excited to partner with AGC Biologics to provide integrated manufacturing solutions that address the complexities of biopharmaceutical development. Together, we are well-positioned to support our clients at every stage."



Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024